fenofibrate has been researched along with Hemangiosarcoma in 1 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Hemangiosarcoma: A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fenofibrate is a hypolipidemic drug, which acts by activating the transcription factor PPARα." | 5.51 | Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. ( Alhousseiny, S; Ding, H; Jameel, M; Majeed, Y; Musthak, A; Shaheen, Y; Taha, T; Triggle, CR; Upadhyay, R, 2019) |
| "Fenofibrate is a hypolipidemic drug, which acts by activating the transcription factor PPARα." | 1.51 | Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. ( Alhousseiny, S; Ding, H; Jameel, M; Majeed, Y; Musthak, A; Shaheen, Y; Taha, T; Triggle, CR; Upadhyay, R, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Majeed, Y | 1 |
| Upadhyay, R | 1 |
| Alhousseiny, S | 1 |
| Taha, T | 1 |
| Musthak, A | 1 |
| Shaheen, Y | 1 |
| Jameel, M | 1 |
| Triggle, CR | 1 |
| Ding, H | 1 |
1 other study available for fenofibrate and Hemangiosarcoma
| Article | Year |
|---|---|
Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro.
Topics: Cell Division; Cell Line, Tumor; Fenofibrate; G2 Phase; Hemangiosarcoma; Humans; Hypolipidemic Agent | 2019 |